Media coverage about Fate Therapeutics (NASDAQ:FATE) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fate Therapeutics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.755341678484 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- Fate Therapeutics, Inc. (FATE) Stock in the Investor Spotlight – Wall Street Morning (wallstreetmorning.com)
- Fate Therapeutics, Inc. (FATE) Raised to Buy at Zacks Investment Research (americanbankingnews.com)
- Fate Therapeutics, Inc. (FATE) Receives Outperform Rating from Leerink Swann (americanbankingnews.com)
- Technicals in View: Tracking Shares of Fate Therapeutics Inc (FATE) – Financial News Review (finnewsreview.com)
- Share Performance in View for Fate Therapeutics, Inc. (NASDAQ:FATE) – Jonesboro Recorder (jonesbororecorder.com)
A number of analysts have recently commented on FATE shares. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a report on Friday, September 8th. ValuEngine upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Tuesday, May 16th. Finally, Leerink Swann restated an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a report on Friday, September 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $6.63.
Fate Therapeutics (NASDAQ FATE) opened at 4.20 on Wednesday. The company’s market cap is $173.94 million. The company has a 50-day moving average of $3.20 and a 200-day moving average of $3.74. Fate Therapeutics has a 52 week low of $1.80 and a 52 week high of $5.68.
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Fate Therapeutics had a negative return on equity of 67.01% and a negative net margin of 887.68%. The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. On average, equities analysts expect that Fate Therapeutics will post ($0.97) EPS for the current year.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.